Parecoxib

• CAT Number: I002517
• CAS Number: 198470-84-7
• Molecular Formula: C19H18N2O4S
• Molecular Weight: 370.42
• Purity: ≥95%
• Synonyms: N-[4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)phenyl]sulfonylpropanamide
• Target: COX
• Solubility: 10 mM in DMSO
• Storage: Store at -20C

Parecoxib (CAT: I002517) is a potent and selective inhibitor of cyclooxygenase-2 (COX-2), an enzyme involved in the synthesis of prostaglandins. By specifically targeting COX-2, parecoxib suppresses the production of prostaglandins, which are associated with inflammation, pain, and fever. Parecoxib’s selective inhibition of COX-2 offers a potential advantage over non-selective NSAIDs by reducing the risk of gastrointestinal complications. It is commonly used as an analgesic and anti-inflammatory agent in the management of acute pain, including postoperative pain, making it a valuable option for pain relief in various clinical settings.

Reference

[1]. Schr?der H, et al. Parecoxib and its metabolite valdecoxib directly interact with cannabinoid binding sites in CB1-expressing HEK 293 cells and rat brain tissue. Neurochem Int. 2011 Jan;58(1):9-13.
[2]. Ye Z, et al. Delayed administration of parecoxib, a specific COX-2 inhibitor, attenuated postischemic neuronal apoptosis by phosphorylation Akt and GSK-3β. Neurochem Res. 2012 Feb;37(2):321-9.
[3]. Guo YJ, et al. Analgesic effects of the COX-2 inhibitor parecoxib on surgical pain through suppression of spinal ERK signaling. Exp Ther Med. 2013 Jul;6(1):275-279.